Glycopyrrolate

Limits on what this shows

• Key null findings: Mitochondrial change is not attributed to glycopyrrolate in the abstract read. No cell-culture, respirometry or membrane-potential study with glycopyrrolate was located.
• At-risk subgroups: None identifiable.

Regulatory status

No mitochondrial statement in the labels read [1][2].

Population evidence

Posey, Boler and Posey 1970 [14]: dogs, electron microscopy after 7 weeks of atropine sulfate, propantheline bromide or glycopyrrolate (vagotomy alone for comparison). "Atropine was accompanied by the most profound mitochondrial derangements"; the summarized read states both atropine and propantheline affected mitochondrial structure; "glycopyrrolate administration was marked by the most extensive cytoplasmic vacuolization", with changes in nucleus and intracellular canaliculus. Doses and animal numbers were not in the read. Two companion 1960s dog papers on long-term glycopyrrolate and parietal-cell function were identified but their abstracts were not read [15].

Mechanism

Plausibly a target-cell adaptation to prolonged blockade of secretion in the parietal cell, not a systemic mitochondrial toxicity. Hard Rule 2: this is the drug acting on its intended tissue, not a nutrient deficiency.

Counter-evidence held on record

Counter-evidence and confounding Single 1970 animal study read through a summarizer; no replication. Keyword tags on an OpenAlex record are not findings and were not used. Framing caution Mechanistic context only. It does not support any statement that glycopyrrolate damages mitochondria in people.

Limits on what this shows

• Key null findings: No human oxidative stress marker study with glycopyrrolate was located. No study showed glycopyrrolate increasing oxidative stress.
• At-risk subgroups: None.

Regulatory status

No oxidative stress statement in the labels read [1][2].

Population evidence

Rat model [16]: adult male Sprague-Dawley rats given concentrated ambient particles; atenolol or glycopyrrolate (0.30 mg/kg, route not stated in the abstract read) "effectively prevented CAPs-induced cardiac oxidative stress" (cardiac chemiluminescence and TBARS). Mouse model [17]: female ICR mice; aerosolized glycopyrronium bromide at 150, 300 and 600 ug/mL before cigarette smoke exposure reduced neutrophil and macrophage recruitment and cytokines, and the summarized read lists glutathione and myeloperoxidase activity as significantly improved at 600 ug/mL; the direction wording for glutathione was ambiguous in the summary.

Mechanism

Present and receptor-based. In the rat study, blocking muscarinic signaling blunted autonomic-driven oxidant generation [16]. These are pathology-model effects in other organs, not a nutrient or antioxidant-capacity measurement in treated people.

Counter-evidence held on record

Counter-evidence and confounding Both studies are animal-only, use injury models and non-oral or unstated routes, and the abstracts were reached through a summarizer or a reconstructed OpenAlex record; the full text was not read. The two studies are independent. Framing caution Reverse-direction context flag. Not a basis for any antioxidant or supplement recommendation.

Limits on what this shows

• Key null findings: No study of iron absorption, ferritin, hemoglobin or iron deficiency in glycopyrrolate users was located. Single-dose pre-anesthetic studies showed little change in gastric pH after glycopyrrolate alone (pH 1.94 vs 1.85 control; n=67 across three groups) [8], which weakens an acid-mediated route.
• At-risk subgroups: None identifiable from the evidence. Children with neurologic disability on long-term therapy and people with other iron-risk factors are contexts, not findings.

Regulatory status

Not mentioned in the glycopyrrolate tablet or oral-solution labels read [1][2] (summarized extracts).

Population evidence

Orrego-Matte 1971 [11]: absorption study of 59Fe ferrous citrate in two species; hexocyclium methosulfate in humans and atropine in rats. "In both species, anticholinergics produced a decrease in absorption"; the effect persisted when iron was given into the stomach with gastric juice and disappeared when iron bypassed the stomach. Subject numbers and magnitudes were not in the abstract read. Schade 1969 [12]: animal study; alpha-adrenergic or parasympathetic blocking agents given by injection slowed intestinal movement and enhanced iron absorption; the specific parasympathetic blocker was not identified in the abstract read.

Mechanism

Partly present. Glycopyrrolate reduces gastric secretion and slows gastric emptying and transit [1][9]. Slowed transit would be expected to raise absorption [12]; an effect on a gastric factor needed for optimal absorption would lower it [11]. The net effect for this drug has not been measured.

Class cohort test

CLASS EXTRAPOLATION, Tier C. Glycopyrrolate was NOT in the cohort of either study: hexocyclium (humans) and atropine (rats) in [11]; an unnamed parasympathetic blocker in [12]. Capped at yellow under Hard Rule 6.

Counter-evidence held on record

Counter-evidence and confounding Confounding by indication is presumed in any treated population (chronic ulcer disease can itself cause blood loss; neurologic disability affects intake). The two class studies point in opposite directions and are decades-old animal and small human experiments. Framing caution Not a deficiency claim for glycopyrrolate and not a reason to change iron intake. No supplement dose is suggested.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source was opened that addresses copper, and no circulating copper claim for glycopyrrolate was found. This is a disclosed gap, not a finding of safety. Kept independent of Iron (Hard Rule 7).

What was searched

Original review: PubMed listing "glycopyrrolate copper": zero records; the web search for copper, ceruloplasmin, zinc and magnesium could not run (budget exhausted). Repair pass: Crossref keyword search "glycopyrrolate copper OR ceruloplasmin OR zinc" returned 15 records, all general copper, zinc and ceruloplasmin papers (lung cancer, infants on parenteral zinc, rat zinc-induced copper deficiency, liver cirrhosis, and similar) and none on glycopyrrolate or any antimuscarinic [29]. The glycopyrrolate injection label [28] and the Cuvposa FDA medical review extract [27] contain no copper statement. No class-level antimuscarinic copper study surfaced in any channel.

Channel outcomes

PubMed HTML search listings: some returned results, several returned HTTP 429 (see Sources); one PubMed article page returned bot-verification. WebSearch: shared budget exhausted partway through the review. Direct database APIs (Crossref, OpenAlex search, DailyMed JSON) returned 429 or were blocked. DailyMed label pages (two) were opened and contained no content for this category. A clean zero on PubMed for the single phrasing tried; ceruloplasmin and zinc phrasings were not completed. Repair pass added one completed channel (Crossref) and two further label or review checks, all empty; the PubMed ceruloplasmin and zinc phrasings were still not run because PubMed was rate-limited. Assessment: mostly a genuine gap, with a residual tooling limit on PubMed.

Limits on what this shows

• Key null findings: The large human and in vitro microbiome studies opened for the cohort test reported no glycopyrrolate or antimuscarinic finding [18][19][20][21]. Crossref keyword searches for glycopyrrolate with microbiota, dysbiosis and bacterial overgrowth returned 15 records, none on glycopyrrolate [29].
• At-risk subgroups: None established.

Regulatory status

No microbiome statement in the tablet, oral-solution or injection labels read [1][2][28]. The contraindication in severe ulcerative colitis and toxic megacolon [28] is a safety contraindication and not microbiome evidence.

Population evidence

Park and Wu 2022 [24], rat arm: 38-week-old male Sprague Dawley rats, n=10 per group, three groups all fed a 43 energy percent high-fat diet. The memory-deficit group received oral water then scopolamine 2 mg/kg intraperitoneally 30 minutes later; the normal group received oral water then saline; a third group received donepezil before scopolamine. Quote: "The relative abundance of Bacteroides and Bilophilia was lower, and that of Escherichia, Blautia, and Clostridium was higher in the scopolamine-induced memory deficit (MD) group than in the normal group." A reported lower Chao1 and Shannon diversity in the "MD" group could not be assigned with certainty to the rat arm or to the companion human analysis in the summary read, so it is not used. The companion human analysis (n=410 pooled from four published studies, healthy versus mild cognitive impairment versus Alzheimer's disease) involved no scopolamine exposure and is not used.

Mechanism

Hypothesis only. The authors frame scopolamine as suppressing parasympathetic activity. Glycopyrrolate is a peripheral antimuscarinic that reduces secretions and slows gastric emptying and transit [1][9][28], which could in principle alter the intestinal environment, but no study links those effects to microbial change for this drug. The authors did not distinguish central from peripheral action, and scopolamine crosses the blood-brain barrier whereas glycopyrrolate shows minimal penetration [6].

Class cohort test

CLASS EXTRAPOLATION, Tier C. Glycopyrrolate was NOT in the cohort; the agent was scopolamine only [24]. Capped at yellow under Hard Rule 6.

Counter-evidence held on record

Counter-evidence and confounding One study, 10 rats per group, a high-fat diet that the authors themselves flag as a limitation ("a high-fat diet itself can change fecal bacteria"), an amnesia-model scopolamine exposure that is not comparable to oral glycopyrrolate, and a central-nervous-system drug. Compositional changes in a memory-impairment model could also follow behavioral or feeding changes. The page was read through a summarizer; full text beyond the summary was not examined. Framing caution Not a statement that glycopyrrolate alters the human gut microbiome. It does not support probiotic or other supplement use, and no dose is suggested.

Limits on what this shows

• Key null findings: Wong-Guerra et al. 2017 [26], rats given scopolamine 1 mg/kg intraperitoneally: the abstract (reconstructed from an OpenAlex record through a summarizer) states "In vitro mitochondrial assays suggest SCO did not affect organelle function directly" and reports no ATP measurement. No glycopyrrolate study of ATP, respiration or mitochondrial membrane potential was found: a Crossref keyword search on glycopyrrolate with ATP, mitochondria and cells returned 15 records, none on glycopyrrolate [29], and the web searches run returned only unrelated mitochondrial-method pages [29].
• At-risk subgroups: None established.

Regulatory status

No energy-metabolism or ATP statement in the labels read [1][2][28].

Population evidence

Abu Almaaty et al. 2021 [25], rats: the aim was to test root or leaf extract of Urtica dioica against scopolamine-induced memory dysfunction, amnesia and oxidative stress. Abstract, read on the Springer page through a summarizer: "UD extracts restored ATP levels and reduced the levels of AMP and ADP compared to SCOP-treated rats." The scopolamine dose, route, tissue analyzed and group sizes were not available in the page read. Full text is subscription-only and was not read.

Mechanism

Not stated. A mitochondrial route is plausible only as a hypothesis. Glycopyrrolate's one drug-specific ultrastructural study [14] is structural and measured no ATP.

Class cohort test

CLASS EXTRAPOLATION, Tier C. Glycopyrrolate was NOT in the cohort of [25] or [26]; the agent was scopolamine only. Capped at yellow under Hard Rule 6.

Counter-evidence held on record

Counter-evidence and confounding Single abstract-level rat study; the lower-ATP direction is inferred from the word "restored" and not read as a measured contrast. Scopolamine is a tertiary, centrally active amine used here to induce amnesia, whereas glycopyrrolate is a quaternary amine with minimal blood-brain barrier penetration [6], so the model's relevance to this drug is limited. A fall in tissue ATP in a toxin or amnesia model is a model outcome and not a nutrient deficiency (Hard Rule 2). Framing caution Not a statement that glycopyrrolate lowers ATP or causes low energy in people, and not a reason to take energy or mitochondrial supplements. No dose is given.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B or C source and no circulating claim found. Any anemia signal would be an outcome and not a nutrient (Hard Rule 2), and would be handled in the Iron entry. Kept independent of ATP production (Hard Rule 7). Disclosed gap, not a finding of safety.

What was searched

Web search "glycopyrrolate anemia OR hemoglobin OR hemolysis OR methemoglobin adverse effect": results were general methemoglobinemia pages, none about glycopyrrolate. PubMed listing "glycopyrrolate hemoglobin": records were unrelated (diabetes, veterinary anesthesia protocols, a lupus case) and were not opened. The labels read list no anemia or hematologic adverse reaction [1][2].

Channel outcomes

PubMed HTML search listings: some returned results, several returned HTTP 429 (see Sources); one PubMed article page returned bot-verification. WebSearch: shared budget exhausted partway through the review. Direct database APIs (Crossref, OpenAlex search, DailyMed JSON) returned 429 or were blocked. DailyMed label pages (two) were opened and contained no content for this category. Repair pass: WebSearch phrasings for hypoxia, sepsis, lung injury, PaO2, hypoxic pulmonary vasoconstriction, endotoxin and cardiopulmonary models with glycopyrrolate returned no glycopyrrolate study (general ARDS, hypoxic vasoconstriction and sepsis papers only); a Crossref search "glycopyrrolate hypoxia oxygenation" returned nine records, none on glycopyrrolate other than a pharmacopeial monograph entry [29]. The glycopyrrolate injection label has no statement on hypoxia, oxygen saturation, hemoglobin or anemia [28]. The FDA medical review of Cuvposa oral solution (summarizer extract) records that a CBC was taken at screening and week 8 in placebo-controlled trial FH-00-01 and at screening and week 24 in an open-label trial, but gave no hematology results in the sections read; its preclinical section states "there were no remarkable effects on hematology, clinical chemistry, mean organ weights, or gross pathology" in animal studies at high doses [27]. That is a null animal-toxicology statement and a lead, not evidence of a physiological effect. PubMed pages (hypoxia listing and a TEE trial record) returned bot-verification or 429, and the open-label pediatric drooling article on Taylor and Francis returned 403 and its PMC copy returned a reCAPTCHA page, so the pediatric laboratory data were not read. Assessment: mostly a genuine gap on the terms tried, with the pediatric drooling hemoglobin data and the full FDA review tables as tooling-blocked follow-ups.